SenzaGen AB (FRA:26S)

Market Cap	12.75M -21.7%
Revenue (ttm)	5.51M +9.3%
Net Income	-835.47K
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.3850
Previous Close	0.3900
Day's Range	0.3850 - 0.3850
52-Week Range	0.3850 - 0.5500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About SenzaGen AB

SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Employees: 34
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 26S

Financial Performance

In 2025, SenzaGen AB's revenue was 57.97 million, an increase of 0.48% compared to the previous year's 57.70 million. Losses were -11.59 million, 3.29% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error